市場調查報告書
商品編碼
1390737
2023-2028 年按產品類型、應用、配銷通路和地區分類的鴉片類藥物市場報告Opioids Market Report by Product Type, Application, Distribution Channel, and Region 2023-2028 |
2022年全球鴉片類藥物市場規模達212億美元。展望未來, IMARC Group預計到2028年市場規模將達到256億美元,2022-2028年複合年成長率(CAGR)為3.19%。慢性疼痛發病率的上升、老年人口的增加、癌症診斷的增加、醫療保健服務的改善、持續的研究和開發(R&D)努力、消費者意識的提高以及有利的政府法規是推動市場的一些主要因素。
鴉片類藥物,也稱為麻醉劑,是一類從罌粟植物中提取或在實驗室合成的強效止痛藥。這些物質作用於大腦和脊髓中的特定受體,主要是μ鴉片受體,以減輕疼痛並引起欣快感。鴉片類藥物可分為兩大類,包括處方鴉片類藥物(由醫療保健專業人員合法處方用於治療劇烈疼痛)和非法鴉片類藥物(如海洛因),在沒有醫療監督的情況下獲取和使用。最常見的處方鴉片類藥物包括羥考酮、氫可酮和芬太尼。
慢性疼痛(包括癌症相關疼痛和肌肉骨骼疾病)的盛行率不斷上升,是需要開立鴉片類藥物來治療嚴重和持續性疼痛的關鍵促進因素。除此之外,全球人口老化導致對鴉片類藥物的需求不斷增加,因為老年人經常經歷與年齡相關的疾病和疼痛。此外,鴉片類藥物通常用於術後疼痛管理,因此全球外科手術的大幅增加正在增加對這些藥物的需求,有助於市場擴張。除此之外,癌症診斷的增加,尤其是在發展中國家,正在推動鴉片類藥物的採用,以治療與癌症相關的疼痛。此外,新興市場醫療保健服務的改善導致鴉片類藥物的處方率更高,因為醫療保健提供者旨在滿足疼痛管理需求,從而推動市場成長。
慢性疼痛的盛行率不斷增加
全球慢性疼痛盛行率不斷上升,是鴉片類藥物市場成長的重要推手。慢性疼痛通常由關節炎、背部問題或神經性疾病等疾病引起,影響數百萬人,因此需要有效的疼痛管理解決方案。鴉片類藥物因其緩解劇烈疼痛的功效而被醫療保健從業者廣泛使用。同時,隨著人口老化和預期壽命的延長,慢性疼痛的發生率也預計會增加,從而推動對鴉片類藥物的需求。除此之外,對疼痛相關疾病的診斷和認知的提高正促使製藥公司投資於研發(R&D),以創造具有更高安全性的創新鴉片類藥物配方,進一步推動市場擴張。
人口老化
全球人口老化是鴉片類藥物市場的另一個關鍵驅動力。老年人經常患有與年齡相關的疾病,包括退化性關節疾病和癌症,導致慢性疼痛的情況增加,這反過來又刺激了對鴉片類藥物等疼痛管理方案的需求。儘管鴉片類藥物具有潛在的副作用和風險,但仍是該族群治療中度至重度疼痛的常用處方選擇。當其他疼痛管理策略被證明不足時,醫療保健提供者經常訴諸鴉片類藥物。這種持續的需求增強了鴉片類藥物市場,因為製藥公司開發了新的配方和給藥方法來滿足老齡化人口的特定需求。
全球癌症發生率上升
癌症診斷發生率的增加,特別是在新興市場,導致對鴉片類藥物的需求激增。癌症通常會出現劇烈疼痛作為常見症狀,而鴉片類藥物是癌症疼痛治療的基石。隨著全球癌症發生率持續上升,對有效止痛措施的需求也在增加,推動了鴉片類藥物市場的成長。此外,醫療保健服務的改善正在導致癌症的早期診斷和治療,因此需要使用鴉片類藥物來控制疼痛。製藥公司正在響應這一需求,開發專門的鴉片類藥物製劑,旨在滿足癌症患者獨特的疼痛狀況,進一步鞏固鴉片類藥物在癌症治療中的作用並推動市場擴張。
IMARC Group提供了全球鴉片類藥物市場報告各細分市場主要趨勢的分析,以及 2023-2028 年全球、區域和國家層面的預測。我們的報告根據產品類型、應用和配銷通路對市場進行了分類。
可待因
芬太尼
美沙酮
羥考酮
嗎啡
氫可酮
羥考酮在市場上佔有最大佔有率
該報告根據產品類型對市場進行了詳細的細分和分析。這包括可待因、芬太尼、美沙酮、羥考酮、嗎啡和氫可酮。根據該報告,羥考酮代表了最大的部分。
羥考酮已成為鴉片類藥物市場的主導產品類型,因為它具有有效的止痛特性,使其能夠非常有效地控制嚴重疼痛,包括術後疼痛和癌症相關疼痛。當其他疼痛治療方法證明不足時,醫生經常會開出羥考酮。此外,製藥業在羥考酮緩釋製劑的開發上投入了大量資金,以更少的給藥間隔提供長期的疼痛緩解。這種便利因素促進了它的廣泛使用。此外,羥考酮的多功能性允許多種給藥途徑,包括口服片劑、膠囊和靜脈製劑,滿足不同患者的需求,這反過來又推動了它的採用。此外,醫療保健提供者對羥考酮的功效和安全性的熟悉程度使其繼續用作疼痛管理的主要選擇,從而為市場成長創造了積極的前景。
疼痛管理
咳嗽治療
腹瀉治療
其他
疼痛管理在市場上佔有最大佔有率
報告還提供了基於應用程式的詳細市場細分和分析。這包括疼痛管理、咳嗽治療、腹瀉治療等。報告稱,疼痛管理佔最大的市場佔有率。
鴉片類藥物在醫療保健領域的基本作用以及人們對有效解決疼痛重要性的日益認知正在推動其在疼痛管理應用中的採用。疼痛是一個普遍而複雜的醫療問題,影響著全世界數百萬人,鴉片類藥物被認為是治療中度至重度疼痛的關鍵組成部分,特別是在急性和慢性疼痛、術後恢復和癌症相關疼痛中。由於老年人口的不斷成長,與疼痛相關的疾病的普遍存在,以及癌症診斷發生率的上升,產生了對鴉片類藥物等有效止痛方法的持續需求,從而促進了市場成長。除此之外,醫學界對改善患者生活品質的承諾導致人們越來越重視個人化疼痛管理計劃,其中鴉片類藥物往往是一個關鍵要素,從而凸顯了其在應用領域的主導地位。
醫院藥房
零售藥局
藥局
網路商店
其他
該報告根據配銷通路對市場進行了詳細的細分和分析。這包括醫院藥局、零售藥局、藥局、網路商店等。
骨關節炎和腰痛等慢性疼痛疾病盛行率的上升,導致零售藥房和藥局鴉片類藥物的處方和購買量激增,從而加強了市場成長。
此外,人們對疼痛管理的認知和倡導不斷增強,促使醫療保健提供者開出鴉片類藥物治療急性疼痛(通常透過醫院藥房獲得),這正在影響市場的成長。
此外,網上購物的便利性和網上藥局的激增使鴉片類藥物更容易獲得,從而促進了產品需求的增加。全球鴉片類藥物市場的動力是需要嚴格的監管、加強教育工作以及所有分銷管道負責任的處方實踐,以在滿足患者緩解疼痛的需求和保障公眾健康之間取得平衡。
北美洲
美國
加拿大
亞太
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
北美表現出明顯的主導地位,佔據最大的鴉片類藥物市場佔有率
市場研究報告還對所有主要區域市場進行了全面分析,其中包括北美(美國和加拿大);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。報告稱,北美佔據最大的市場佔有率。
由於多種因素,北美鴉片類藥物市場經歷了大幅成長,包括背痛和骨關節炎等慢性疼痛疾病的高盛行率、人口老化以及鴉片類藥物在疼痛管理中的廣泛使用。除此之外,醫療基礎設施的改善和對疼痛管理選擇的認知提高導致鴉片類藥物處方率上升,對市場成長產生了積極影響。此外,鴉片類藥物的流行以成癮率和服藥過量死亡率高為特徵,透過增加使用丁丙諾啡和美沙酮等藥物進行成癮治療和減少傷害,刺激了成長。專門的成癮治療中心和藥房已經成為分銷管道,滿足了對這些藥物的需求。此外,在更嚴格的指導方針和處方監控計劃的影響下,不斷發展的法規和處方實踐正在影響市場的成長。
領先的製藥公司正在大力投資研發,以開發創新的鴉片類藥物配方。這些努力的重點是創造具有改進的安全性、減少濫用可能性並增強疼痛管理功效的鴉片類藥物。目標是為醫療保健專業人員提供更有效、更安全的治療選擇。此外,鴉片類藥物製造商正在密切監控並遵守與鴉片類藥物處方、分銷和使用相關的不斷變化的法規和指南。他們正在努力確保其產品符合最高的安全和品質標準,同時遵守嚴格的監管要求。所有這些努力正在塑造鴉片類藥物市場的未來。
勃林格殷格翰國際股份有限公司
希克馬製藥公司
馬林克羅特公司
輝瑞公司
普渡製藥公司
賽諾菲公司
太陽製藥工業有限公司
梯瓦製藥工業股份有限公司
2021年6月,美國FDA受理並授予Purdue Pharma LP提交的鹽酸納美芬注射新藥申請(NDA)優先審查資格。納美芬注射是一種鴉片拮抗劑,旨在逆轉鴉片類藥物過量。
2022 年 11 月,Teva 宣布與 Rimidi 建立新型合作夥伴關係,以擴大呼吸數位健康平台的影響力。
The global opioids market size reached US$ 21.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 25.6 Billion by 2028, exhibiting a growth rate (CAGR) of 3.19% during 2022-2028. The rising incidence of chronic pain conditions, expanding elderly population, increase in cancer diagnoses, improved access to healthcare services, ongoing research and development (R&D) efforts, escalating consumer awareness, and favorable government regulations are some of the major factors propelling the market.
Opioids, also known as narcotics, are a class of powerful pain-relieving medications derived from the opium poppy plant or synthesized in laboratories. These substances act on specific receptors in the brain and spinal cord, primarily the mu-opioid receptors, to alleviate pain and induce a sense of euphoria. Opioids can be classified into two main categories including, prescription opioids, which are legally prescribed by healthcare professionals to manage severe pain, and illicit opioids like heroin, which are obtained and used without medical supervision. The most common prescription opioids include oxycodone, hydrocodone, and fentanyl.
The expanding prevalence of chronic pain conditions, including cancer-related pain and musculoskeletal disorders, is a key driving factor necessitating the prescription of opioids for the management of severe and persistent pain. In addition to this, the global demographic shift towards an aging population is contributing to the increasing demand for opioids, as elderly individuals frequently experience age-related ailments and pain. Moreover, opioids are commonly used in post-operative pain management, consequently the significant surge in surgical procedures worldwide is boosting the demand for these medications, thereby aiding in market expansion. Besides this, the increase in cancer diagnoses, especially in developing countries, is fueling the adoption of opioids to manage cancer-related pain. Furthermore, improved access to healthcare services in emerging markets is leading to higher prescription rates for opioids as healthcare providers aim to address pain management needs, thus impelling the market growth.
Increasing prevalence of chronic pain
The escalating prevalence of chronic pain across the globe represents a significant growth-inducing driver of the opioids market. Chronic pain, often resulting from conditions such as arthritis, back problems, or neuropathic disorders, affects millions of individuals, necessitating effective pain management solutions. Opioids are widely prescribed by healthcare practitioners due to their potency in alleviating severe pain. Concurrent with this, as the population ages and life expectancy rises, the incidence of chronic pain is also expected to grow, propelling the demand for opioids. Besides this, improved diagnosis and awareness of pain-related disorders are prompting pharmaceutical companies to invest in research and development (R&D) to create innovative opioid formulations with enhanced safety profiles, further driving the market's expansion.
Aging population
The global demographic shift toward an aging population is another key driver of the opioids market. Elderly individuals often experience age-related ailments, including degenerative joint diseases and cancer, leading to increased instances of chronic pain, which, in turn, is fueling the demand for pain management options, such as opioids. Opioids, despite their potential side effects and risks, remain a commonly prescribed option for managing moderate to severe pain in this demographic. Healthcare providers often resort to opioids when other pain management strategies prove inadequate. This sustained demand has strengthened the opioid market, as pharmaceutical companies develop new formulations and delivery methods to cater to the specific needs of the aging population.
Rising cancer rates across the globe
The increasing incidence of cancer diagnoses, particularly in emerging markets, is contributing to the surging demand for opioids. Cancer often presents severe pain as a common symptom, and opioids are a cornerstone of cancer pain management. As cancer rates continue to rise globally, so does the demand for effective pain relief measures, fueling the opioid market's growth. Moreover, improved access to healthcare services is leading to earlier cancer diagnosis and treatment, necessitating the use of opioids for pain management. Pharmaceutical companies are responding to this demand by developing specialized opioid formulations designed to cater to the unique pain profiles of cancer patients, further solidifying the role of opioids in cancer care and driving market expansion.
IMARC Group provides an analysis of the key trends in each segment of the global opioids market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product type, application and distribution channel.
Codeine
Fentanyl
Methadone
Oxycodone
Morphine
Hydrocodone
Oxycodone holds the largest share in the market
The report has provided a detailed breakup and analysis of the market based on the product type. This includes codeine, fentanyl, methadone, oxycodone, morphine, and hydrocodone. According to the report, oxycodone represented the largest segment.
Oxycodone has emerged as a dominant product type in the opioids market for owing to its potent pain-relieving properties which make it highly effective in managing severe pain, including post-operative and cancer-related pain. Physicians often prescribe oxycodone when other pain management options prove insufficient. Moreover, the pharmaceutical industry has invested significantly in the development of extended-release formulations of oxycodone, offering prolonged pain relief with fewer dosing intervals. This convenience factor has contributed to its widespread use. Additionally, oxycodone's versatility allows for various administration routes, including oral tablets, capsules, and intravenous formulations, catering to diverse patient needs, which, in turn, is impelling its adoption. Moreover, the familiarity of healthcare providers with oxycodone's efficacy and safety profile has led to its continued use as a primary option for pain management, creating a positive outlook for market growth.
Pain Management
Cough Treatment
Diarrhea Treatment
Others
Pain management holds the largest share in the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes pain management, cough treatment, diarrhea treatment, and others. According to the report, pain management accounted for the largest market share.
Opioid's fundamental role in healthcare sector and the increasing recognition of the importance of effectively addressing pain is fueling its adoption in pain management applications. Pain is a pervasive and complex medical issue affecting millions of individuals worldwide, and opioids are considered a crucial component in managing moderate to severe pain, especially in acute and chronic pain conditions, post-surgical recovery, and cancer-related pain. The sheer prevalence of pain-related conditions owing to the growing geriatric population, and the rising incidence of cancer diagnoses have created a sustained demand for effective pain relief methods, such as opioids, thereby bolstering the market growth. In addition to this, the medical community's commitment to improving the quality of life for patients has led to a growing emphasis on personalized pain management plans, where opioids are often a key element, thus, underscoring its dominance in the application segment.
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Stores
Others
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, drug stores, online stores, and others.
The rise in prevalence of chronic pain conditions, such as osteoarthritis and lower back pain, has led to a surge in the prescription and purchase of opioid medications through retail pharmacies and drug stores, strengthening the market growth.
Additionally, the growing awareness and advocacy for pain management prompting healthcare providers to prescribe opioids for acute pain, often obtained through hospital pharmacies is influencing the market's growth.
Furthermore, the convenience of online shopping and the proliferation of online pharmacies has made opioids more accessible, contributing to increased product demand. The global opioids market is driven by the need for stringent regulations, enhanced educational efforts, and responsible prescribing practices across all distribution channels to strike a balance between meeting patients' pain relief needs and safeguarding public health.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest opioids market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The North American opioids market has experienced substantial growth due to several factors, including a high prevalence of chronic pain conditions, such as back pain and osteoarthritis, an aging population, and the widespread use of opioids in pain management. In addition to this, improved healthcare infrastructure and increased awareness of pain management options have led to higher opioid prescription rates, positively impacting the market growth. Moreover, the opioid epidemic, characterized by high rates of addiction and overdose deaths, has spurred growth through the increased use of medications such as buprenorphine and methadone for addiction treatment and harm reduction. Specialized addiction treatment centers and pharmacies have emerged as distribution channels, addressing the demand for these medications. Furthermore, evolving regulations and prescribing practices, influenced by stricter guidelines and prescription monitoring programs are influencing the market growth.
Leading pharmaceutical companies are investing heavily in R&D to develop innovative opioid formulations. These efforts focus on creating opioids with improved safety profiles, reduced potential for abuse, and enhanced efficacy in pain management. The goal is to provide healthcare professionals with more effective and safer treatment options. Moreover, opioid manufacturers are closely monitoring and complying with evolving regulations and guidelines related to opioid prescribing, distribution, and usage. They are working to ensure that their products meet the highest safety and quality standards while adhering to stringent regulatory requirements. All these efforts are shaping the future of the opioids market.
Boehringer Ingelheim International GmbH
Hikma Pharmaceuticals PLC
Mallinckrodt plc
Pfizer Inc.
Purdue Pharma L.P.
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
In June 2021, the U.S. FDA accepted and granted priority review designation to new drug application (NDA) submitted by Purdue Pharma L.P. for nalmefene hydrochloride injection. Nalmefene injectable is an opioid antagonist designed to reverse opioid overdose.
In November 2022, Teva announced a novel partnership with Rimidi to broaden the respiratory digital health platform's impact.